Nona Biosciences, a cutting-edge technology innovator and wholly-owned subsidiary of HBM Holdings Limited, has entered into an exciting collaboration with Mythic Therapeutics, a biotechnology company that is developing revolutionary antibody-drug conjugate-based (ADC) therapies for cancer treatments. Together, the two companies are combining their expertise to bring the concept of “Idea to IND” (“I to ITM”) to life, creating a comprehensive solution for cancer patients around the world.
Nona Biosciences and Mythic Therapeutics have joined forces to use Nona’s proprietary fully human heavy chain only antibody (HCAb) transgenic mice platform and antibody generation services as the basis for Mythic Therapeutics’ innovative FateControl™ antibody engineering approach to create next-generation ADCs for the treatment of a range of cancers. By combining Nona’s cutting-edge technology with Mythic’s groundbreaking approach, they hope to revolutionize the field of cancer treatments.
We are thrilled to partner with Mythic Therapeutics to drive the next-generation of biotherapeutic innovation! Our expertise in ADC drug discovery, combined with our tried and tested therapeutic antibody platforms, have been endorsed by a multitude of partners worldwide. Mythic Therapeutics boasts an impressive foundation and top-tier team in the field of oncology, making them a perfect fit to further progress target discovery, with the ultimate goal of providing successful treatments for unmet medical needs. Jingsong Wang MD, PhD, Chairman of Nona Biosciences, expressed his excitement over the collaboration.
HCAb’s revolutionary technology is revolutionizing the antibody world, creating novel “heavy chain only” antibodies that are about half the size of a typical IgG. These antibodies boast IgG-like PK properties and Fc-domain functions, while avoiding the issue of light chain mispairing and heterodimerization. This new platform opens up the potential for a range of novel therapeutic and diagnostic products, including single-domain antibodies, bi- and multi-specifics, antibody-drug conjugates, CAR-Ts, and VH domain-derived products. It’s clear that HCAb’s technology has the potential to revolutionize the field of antibody development.
About Nona Biosciences
Nona Biosciences, a subsidiary of HBM Holdings (HKEX: 02142), is revolutionizing the biotechnology industry with cutting-edge technology and a comprehensive “Idea to IND” (“I to ITM”) solution. Through our integrated antibody and antibody-related discovery services with multiple modalities, including antigen preparation, animal immunization, single B cell screening, antibody lead generation and engineering, developability assessment and pharmacological evaluation, we are leveraging the power of Harbour Mice® platforms and our experienced therapeutic antibody discovery team to create something truly special.
Harbour Mice® is revolutionizing the development of therapeutic monoclonal antibodies by generating fully human H2L2 and HCAb format antibodies. By combining the Harbour Mice® technology with a single B cell cloning platform, Nona Biosciences is pioneering the development of groundbreaking next-generation drugs that will transform the healthcare industry.